Subscribe
shutterstock_281684060_mark_van_scyoc
Mark Van Scyoc / Shutterstock.com
16 April 2020AmericasSarah Morgan

States join antitrust suit against ‘pharma bro’ Shkreli

Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company  Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Shkreli inflated price of life-saving drug from federal prison, FTC says
14 August 2020   Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.
Americas
Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30 July 2020   Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.
Americas
US states sue 26 drugmakers over alleged price fixing
11 June 2020   A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Big Pharma
Shkreli inflated price of life-saving drug from federal prison, FTC says
14 August 2020   Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.
Americas
Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30 July 2020   Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.
Americas
US states sue 26 drugmakers over alleged price fixing
11 June 2020   A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.

More on this story

Big Pharma
Shkreli inflated price of life-saving drug from federal prison, FTC says
14 August 2020   Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.
Americas
Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30 July 2020   Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.
Americas
US states sue 26 drugmakers over alleged price fixing
11 June 2020   A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.

More features

Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders
Former PTAB judge joins Sterne Kessler
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space